Professor Craig Ritchie
Chair of the Psychiatry of Ageing and Director of the Centre for Dementia Prevention
- Centre for Clinical Brain Sciences
- Centre for Dementia Prevention
- Wellcome Trust Clinical Research Facility (Edinburgh)
Contact details
- Email: craig.ritchie@ed.ac.uk
Background
Prof Ritchie is currently Professor of the Psychiatry of Ageing at the University of Edinburgh having moved from his role as Senior Lecturer in the Centre for Mental Health at Imperial College London in October 2014.
Research summary
Professor Ritchie is a leading authority on Clinical Trials in Dementia and has been senior investigator on over 30 drug trials of both disease modifying and symptomatic agents for that condition. This emerged from his ongoing clinical leadership of the MPAC (Metal Protein Attenuating Compound) pipeline for Prana Biotechnology dating back to 1998 when he worked as a Senior Visiting Research Fellow at the Mental Health Research Institute in Victoria, Australia. He has sat on advisory boards of numerous pharmaceutical companies, biotechs and clinical research organizations with an in interest in developing drugs and trials infrastructure for Alzheimer’s disease.
He has published extensively on the topics of dementia and delirium including clinical trials and meta-analyses. He sits on several advisory boards for major pharmaceutical and biotechnology companies as well as The Wellcome Trust and the Public Health Steering Group for the Alzheimer’s Society. He is also one of the leading editors in the Cochrane Collaboration’s Dementia Group with a particular specialism in Diagnostic Test Accuracy reviews and is Assistant Editor for the journal International Psychogeriatrics.
He is leading the PREVENT project; a major initiative nationally which will identify mid-life risks for later life dementia and characterize early changes of neurodegenerative disease through imaging, genetic, cognitive and biomarker analyses.
He also leads the EPAD (European Prevention of Alzheimer’s Dementia) Consortium which is an IMI funded, 5-year grant application to establish a Pan-European network of Trial Delivery Centers with supporting infrastructure to undertake a perpetual, Proof of Concept multi-arm trial secondary trial for secondary prevention of Alzheimer’s dementia. This work will be led from Edinburgh.
-
Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer's Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments
In:
Trials, vol. 23, pp. 623
DOI: https://doi.org/10.1186/s13063-022-06190-3
Research output: Contribution to Journal › Article (E-pub ahead of print) -
The Open-Access European Prevention of Alzheimer’s Dementia (EPAD) MRI dataset and processing workflow
In:
NeuroImage: Clinical, vol. 35, pp. 103106
DOI: https://doi.org/10.1016/j.nicl.2022.103106
Research output: Contribution to Journal › Article (E-pub ahead of print) -
Impact of cerebral blood flow and amyloid load on SUVR bias
In:
EJNMMI research, vol. 12, pp. 29
DOI: https://doi.org/10.1186/s13550-022-00898-8
Research output: Contribution to Journal › Article (E-pub ahead of print) -
Fluid-attenuated inversion recovery magnetic resonance imaging textural features as sensitive markers of white matter damage in midlife adults
In:
Brain Communications, vol. 4
DOI: https://doi.org/10.1093/braincomms/fcac116
Research output: Contribution to Journal › Article (Published) -
Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios
(12 pages)
In:
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, vol. 14
DOI: https://doi.org/10.1002/dad2.12314
Research output: Contribution to Journal › Article (Published)